Patents by Inventor Kendal T. Ryter

Kendal T. Ryter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Diaryl trehalose compounds and uses thereof
    Patent number: 11912736
    Abstract: Disclosed herein are diaryl trehalose compounds and methods of use thereof, for example as vaccine adjuvants.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: February 27, 2024
    Assignee: THE UNIVERSITY OF MONTANA
    Inventors: David Burkhart, George Ettenger, Jay Evans, Kendal T. Ryter, Alyson Smith
  • TOLL-LIKE RECEPTOR LIGANDS
    Publication number: 20230055805
    Abstract: Toll-like receptor (TLR) ligands having an allose-based core are stable in aqueous formulation and are useful in treating, preventing, or reducing susceptibility to diseases or conditions mediated by TLRs, such as cancer, infectious disease, allergy, autoimmune disease, sepsis, and ischemia reperfusion.
    Type: Application
    Filed: August 29, 2022
    Publication date: February 23, 2023
    Inventors: Helene Bazin-Lee, George Ettenger, Juhienah Khalaf, Kendal T. Ryter
  • Immunogenic trehalose compounds and uses thereof
    Patent number: 11572381
    Abstract: Disclosed herein are immunogenic trehalose compounds and methods of use thereof, for example as vaccine adjuvants.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: February 7, 2023
    Assignee: The University of Montana
    Inventors: David Burkhart, Jay Evans, Craig Johnson, Kendal T. Ryter, Alyson Smith, Walid Abdelwahab Marzouky Abdelwahab
  • Toll-like receptor ligands
    Patent number: 11458151
    Abstract: Toll-like receptor (TLR) ligands having an allose-based core are stable in aqueous formulation and are useful in treating, preventing, or reducing susceptibility to diseases or conditions mediated by TLRs, such as cancer, infectious disease, allergy, autoimmune disease, sepsis, and ischemia reperfusion.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: October 4, 2022
    Assignee: INIMMUNE CORPORATION
    Inventors: Helene Bazin-Lee, George Ettenger, Juhienah Khalaf, Kendal T. Ryter
  • DIARYL TREHALOSE COMPOUNDS AND USES THEREOF
    Publication number: 20210139521
    Abstract: Disclosed herein are diaryl trehalose compounds and methods of use thereof, for example as vaccine adjuvants.
    Type: Application
    Filed: February 21, 2019
    Publication date: May 13, 2021
    Inventors: David Burkhart, George Ettenger, Jay Evans, Kendal T. Ryter, Alyson Smith
  • TOLL-LIKE RECEPTOR LIGANDS
    Publication number: 20210023106
    Abstract: Toll-like receptor (TLR) ligands having an allose-based core are stable in aqueous formulation and are useful in treating, preventing, or reducing susceptibility to diseases or conditions mediated by TLRs, such as cancer, infectious disease, allergy, autoimmune disease, sepsis, and ischemia reperfusion.
    Type: Application
    Filed: February 12, 2019
    Publication date: January 28, 2021
    Inventors: Helene Bazin-Lee, George Ettenger, Juhienah Khalaf, Kendal T. Ryter
  • IMMUNOGENIC TREHALOSE COMPOUNDS AND USES THEREOF
    Publication number: 20200369704
    Abstract: Disclosed herein are immunogenic trehalose compounds and methods of use thereof, for example as vaccine adjuvants.
    Type: Application
    Filed: March 1, 2019
    Publication date: November 26, 2020
    Inventors: David Burkhart, Jay Evans, Craig Johnson, Kendal T. Ryter, Alyson Smith, Walid Abdelwahab Marzouky Abdelwahab